Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Sichuan University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05466318CT.gov ChiCGB vs BEAM in High-risk or R/R Lymphomas | — | Unknown | — | — | — |
NCT05367856CT.gov Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma | — | Unknown | — | — | — |
NCT00992446CT.gov Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · T-Cell Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Camustine (this asset) | Sichuan University | P3 | B · 62 |
| Fludarabine | GC Cell Corporation | P2 | BBB |
| Brentuximab Vedotin | Yale University | P4 | BBB |
| Rituximab | Memorial Sloan Kettering Cancer Center | P2 | BB |
| Cyclophosphamide | GC Cell Corporation | P3 | BB |
| Lenalidomide | Samsung Medical Center | P2 | BB |
| Tacrolimus | M.D. Anderson Cancer Center | P2 | BB |
| Melphalan | Sichuan University | P3 | BB |
| Busulfanum | Sichuan University | P3 | BB |
+42 more in the T-Cell Non-Hodgkin Lymphoma cohort
Other indications for Camustine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hodgkins Lymphoma | — | P2 | BBB · 74 |
| B-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 73 |
| Central Nervous System Neoplasm | — | P3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Camustine in T-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/camustine-t-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →